Ocugen, Inc. (OCGN) 10-Year Financial Performance & Capital Metrics

OCGN • • Industrial / General

HealthcareBiotechnologyRare Genetic DiseasesGene Therapy & Rare Diseases

AboutOcugen, Inc., a clinical-stage biopharmaceutical company, focuses on the developing gene therapies to cure blindness diseases. The company's pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, such as retinitis pigmentosa and leber congenital amaurosis; OCU410, gene therapy candidate for the treatment of dry age-related macular degeneration (AMD); and OCU200, a novel fusion protein that is in preclinical development stage for the treatment of diabetic macular edema, diabetic retinopathy, and wet AMD. Ocugen, Inc. has a strategic partnership with CanSino Biologics Inc. for gene therapy co-development and manufacturing; and Bharat Biotech for the commercialization of COVAXIN in the United States market. The company is headquartered in Malvern, Pennsylvania.Show more

Revenue $4M -32.8%
EBITDA -$53M +18.6%
Net Income -$54M +14.3%
EPS (Diluted) -0.20 +23.1%
Gross Margin 51.47% -41.7%
EBITDA Margin -1301.82% -21.2%
Operating Margin -1350.36% -24.4%
Net Margin -1333.02% -27.6%
ROE -154.01% -39.8%
ROIC -704.18% +22.4%
Debt/Equity 1.10 +541.0%
Interest Coverage -

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Momentum leader: RS Rating 92 (top 8%)

✗Weaknesses

✗Weak Piotroski F-Score: 2/9
✗Negative free cash flow
✗Shares diluted 10.9% in last year
✗Expensive at 14.8x book value
✗Low asset turnover indicates capital-intensive operations

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-

5Y-

3Y-

TTM-42.43%

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM-28.9%

EPS CAGR

10Y-

5Y-

3Y-

TTM-23.32%

ROCE

10Y Avg-120.06%

5Y Avg-103.27%

3Y Avg-101.15%

Latest-101.11%

Peer Comparison

Gene Therapy & Rare Diseases

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
KRYSKrystal Biotech, Inc.	8.18B	282.01	94.00	473.02%	53.3%	17.48%	1.46%	0.01
BMRNBioMarin Pharmaceutical Inc.	10.58B	55.07	24.92	17.97%	16.82%	8.59%	4.49%	0.11
SRPTSarepta Therapeutics, Inc.	2.23B	21.31	9.11	52.97%	-11.25%	-20.57%		0.88
RAREUltragenyx Pharmaceutical Inc.	2.27B	23.50	-3.74	29.01%	-91.95%	-35.88%		0.15
DYNDyne Therapeutics, Inc.	2.7B	16.42	-4.87			-61.26%		0.04
TVTXTravere Therapeutics, Inc.	2.54B	28.40	-6.96	60.55%	-20.32%	-120.36%		6.80
BEAMBeam Therapeutics Inc.	3.25B	32.05	-7.00	-83.18%	-7.44%	-42.92%		0.22
SLNOSoleno Therapeutics, Inc.	2.25B	41.95	-9.58		-79.5%	-15.85%		0.22

Profit & Loss

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	0	0	0	0	0	43K	0	2.49M	6.04M	4.05M
Revenue Growth %	-	-	-	-	-	-	-1%	-	1.43%	-0.33%
Cost of Goods Sold+	1.61M	1.67M	1.53M	49.62K	8.09M	6.35M	0	0	704K	1.97M
COGS % of Revenue	-	-	-	-	-	147.77%	-	-	0.12%	0.49%
Gross Profit+	-1.61M	-1.67M	-1.53M	-49.62K	-8.09M	-6.31M	0	2.49M	5.33M	2.09M
Gross Margin %	-	-	-	-	-	-146.77%	-	1%	0.88%	0.51%
Gross Profit Growth %	-	-0.04%	0.08%	0.97%	-161.95%	0.22%	1%	-	1.14%	-0.61%
Operating Expenses+	31.51M	30.11M	24.95M	25.84M	6.08M	14.97M	58.03M	91.56M	70.86M	56.84M
OpEx % of Revenue	-	-	-	-	-	348.23%	-	36.8%	11.74%	14.02%
Selling, General & Admin	8.27M	8.53M	9.38M	10.2M	6.08M	7.97M	22.92M	35.4M	31.99M	26.69M
SG&A % of Revenue	-	-	-	-	-	185.44%	-	14.23%	5.3%	6.58%
Research & Development	23.24M	21.58M	15.57M	15.63M	8.09M	13.35M	35.11M	56.16M	39.57M	32.13M
R&D % of Revenue	-	-	-	-	-	310.56%	-	22.57%	6.56%	7.92%
Other Operating Expenses	-72K	-248K	-116K	0	-8.09M	-6.35M	0	0	-704K	-1.97M
Operating Income+	-31.82M	-30.31M	-24.95M	-30.11M	-14.16M	-21.29M	-58.03M	-89.07M	-65.53M	-54.76M
Operating Margin %	-	-	-	-	-	-495%	-	-35.8%	-10.86%	-13.5%
Operating Income Growth %	0.03%	0.05%	0.18%	-0.21%	0.53%	-0.5%	-1.73%	-0.53%	0.26%	0.16%
EBITDA+	-30.2M	-28.63M	-23.42M	-30.06M	-14.1M	-21.18M	-57.8M	-88.59M	-64.83M	-52.79M
EBITDA Margin %	-	-	-	-	-	-492.63%	-	-35.61%	-10.74%	-13.02%
EBITDA Growth %	0.05%	0.05%	0.18%	-0.28%	0.53%	-0.5%	-1.73%	-0.53%	0.27%	0.19%
D&A (Non-Cash Add-back)	1.61M	1.67M	1.53M	49.62K	61K	102K	229K	480K	704K	1.97M
EBIT	-31.89M	-13.05M	-26.41M	-14.47M	-14.16M	-14.29M	-58.03M	-89.07M	-65.53M	-54.76M
Net Interest Income+	0	0	0	0	-1.77M	-719.9K	-79K	1.4M	2.5M	1.3M
Interest Income	0	0	0	0	1.21K	1.06K	0	1.4M	2.5M	1.3M
Interest Expense	-133K	-60K	134K	163K	1.77M	720.96K	79K	0	0	0
Other Income/Expense	-205K	14.1M	-1.46M	11.89M	-6.08M	-537K	-389K	2.27M	2.45M	703K
Pretax Income+	-32.02M	-16.21M	-26.41M	-8.64M	-20.24M	-21.82M	-58.42M	-86.8M	-63.08M	-54.05M
Pretax Margin %	-	-	-	-	-	-507.49%	-	-34.89%	-10.45%	-13.33%
Income Tax+	0	0	-186K	-15.76M	0	0	-52K	0	0	0
Effective Tax Rate %	1%	1%	1%	1%	1%	1%	1%	1%	1%	1%
Net Income+	-32.02M	-16.21M	-26.41M	-8.64M	-20.24M	-21.82M	-58.37M	-86.8M	-63.08M	-54.05M
Net Margin %	-	-	-	-	-	-507.49%	-	-34.89%	-10.45%	-13.33%
Net Income Growth %	-0.4%	0.49%	-0.63%	0.67%	-1.34%	-0.08%	-1.67%	-0.49%	0.27%	0.14%
Net Income (Continuing)	-32.02M	-16.21M	-26.41M	-18.22M	-20.24M	-21.82M	-58.37M	-86.8M	-63.08M	-54.05M
Discontinued Operations	0	0	0	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0
EPS (Diluted)+	-145.22	-67.58	-69.91	-13.98	-1.53	-0.31	-0.30	-0.40	-0.26	-0.20
EPS Growth %	0.84%	0.53%	-0.03%	0.8%	0.89%	0.8%	0.03%	-0.33%	0.35%	0.23%
EPS (Basic)	-145.22	-68.21	-69.91	-13.98	-1.53	-0.31	-0.30	-0.40	-0.26	-0.20
Diluted Shares Outstanding	220.52K	239.82K	377.84K	618.18K	13.89M	112.24M	195.01M	214.6M	244.33M	271M
Basic Shares Outstanding	220.52K	237.62K	377.83K	618.18K	13.89M	112.24M	195.01M	214.6M	244.33M	271M
Dividend Payout Ratio	-	-	-	-	-	-	-	-	-	-

Balance Sheet

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	31.24M	32.08M	8.18M	16.4M	15.77M	25.88M	102.65M	98.49M	42.97M	61.68M
Cash & Short-Term Investments	30.91M	31.91M	7.98M	15.54M	7.44M	24.04M	94.96M	90.93M	39.46M	58.51M
Cash Only	30.91M	31.91M	7.08M	15.54M	7.44M	24.04M	94.96M	77.56M	39.46M	58.51M
Short-Term Investments	0	0	900K	0	0	0	0	13.37M	0	0
Accounts Receivable	0	0	0	0	0	0	0	0	0	0
Days Sales Outstanding	-	-	-	-	-	-	-	-	-	-
Inventory	0	0	0	0	0	0	0	0	0	0
Days Inventory Outstanding	-	-	-	-	-	-	-	-	-	-
Other Current Assets	279K	78K	122K	172K	7M	0	0	7.56M	3.51M	3.17M
Total Non-Current Assets+	5.55M	4M	2.86M	1.03M	1.04M	1.5M	3.12M	10.14M	21.58M	20.76M
Property, Plant & Equipment	5.21M	3.86M	2.72M	141K	222.46K	633K	1.16M	6.05M	17.29M	16.55M
Fixed Asset Turnover	-	-	-	-	-	0.07x	-	0.41x	0.35x	0.24x
Goodwill	0	0	0	0	0	0	0	0	0	0
Intangible Assets	200K	0	0	0	0	0	0	0	0	0
Long-Term Investments	0	0	137K	150.48K	151.02K	0	0	0	0	0
Other Non-Current Assets	137K	137K	0	736.52K	667.75K	865K	1.95M	4.09M	4.29M	4.21M
Total Assets+	36.79M	36.08M	11.04M	17.43M	16.81M	27.38M	105.76M	108.63M	64.55M	82.44M
Asset Turnover	-	-	-	-	-	0.00x	-	0.02x	0.09x	0.05x
Asset Growth %	-0.44%	-0.02%	-0.69%	0.58%	-0.04%	0.63%	2.86%	0.03%	-0.41%	0.28%
Total Current Liabilities+	6.36M	5.17M	3.81M	2.87M	4.54M	3.61M	7M	28.53M	17.09M	21.59M
Accounts Payable	2.25M	1.95M	776K	1.59M	1.9M	395K	2.31M	8.06M	3.17M	4.24M
Days Payables Outstanding	509.51	425	184.64	11.7K	85.57	22.69	-	-	1.64K	786.94
Short-Term Debt	583K	583K	178K	0	0	234K	0	0	0	1.33M
Deferred Revenue (Current)	1000K	1000K	1000K	1000K	1000K	0	0	1000K	1000K	1000K
Other Current Liabilities	2.77M	1.24M	1.18M	948K	-2.06M	1.68M	1.72M	3.11M	1.03M	5.25M
Current Ratio	4.91x	6.20x	2.15x	5.71x	3.47x	7.16x	14.66x	3.45x	2.51x	2.86x
Quick Ratio	4.91x	6.20x	2.15x	5.71x	3.47x	7.16x	14.66x	3.45x	2.51x	2.86x
Cash Conversion Cycle	-	-	-	-	-	-	-	-	-	-
Total Non-Current Liabilities+	2.23M	17.34M	18.5M	15.01M	1.25M	2.21M	2.94M	6.12M	6.89M	31.22M
Long-Term Debt	761K	178K	0	1.02M	1.07M	1.82M	1.71M	2.29M	2.8M	27.34M
Capital Lease Obligations	0	0	0	0	163.2K	389K	1.23M	3.59M	3.57M	3.31M
Deferred Tax Liabilities	0	0	0	-1.02M	0	0	0	0	918K	0
Other Non-Current Liabilities	1.47M	17.16M	18.5M	4M	9.76K	0	0	244K	527K	564K
Total Liabilities	8.59M	22.51M	22.3M	17.89M	5.79M	5.83M	9.94M	34.65M	23.98M	52.81M
Total Debt+	1.34M	761K	178K	238K	1.41M	2.49M	3.31M	6.37M	6.94M	32.5M
Net Debt	-29.57M	-31.15M	-6.9M	-15.3M	-6.04M	-21.55M	-91.65M	-71.19M	-32.52M	-26.01M
Debt / Equity	0.05x	0.06x	-	-	0.13x	0.12x	0.03x	0.09x	0.17x	1.10x
Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Net Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Interest Coverage	-	-	-186.19x	-184.71x	-8.01x	-29.52x	-734.53x	-	-	-
Total Equity+	28.2M	13.57M	-11.27M	-458K	11.02M	21.55M	95.82M	73.98M	40.56M	29.63M
Equity Growth %	-0.48%	-0.52%	-1.83%	0.96%	25.06%	0.96%	3.45%	-0.23%	-0.45%	-0.27%
Book Value per Share	127.87	56.57	-29.82	-0.74	0.79	0.19	0.49	0.34	0.17	0.11
Total Shareholders' Equity	28.2M	13.57M	-11.27M	-458K	11.02M	21.55M	95.82M	73.98M	40.56M	29.63M
Common Stock	132K	159K	159K	513K	527.47K	1.84M	2M	2.22M	2.57M	2.92M
Retained Earnings	-165.56M	-181.77M	-208.19M	-216.83M	-51.48M	-73.3M	-131.67M	-223.09M	-286.17M	-340.22M
Treasury Stock	0	0	0	0	-47.86K	-48K	-48K	-48K	-48K	-48K
Accumulated OCI	-7.99M	-9.39M	-10.92M	-10.29M	0	0	0	26K	20K	48K
Minority Interest	0	0	0	0	0	0	0	0	0	0

Cash Flow

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	-30.03M	-25.74M	-23.02M	-15.78M	-16.89M	-14.71M	-47.94M	-60.08M	-62.05M	-42.14M
Operating CF Margin %	-	-	-	-	-	-342.06%	-	-24.15%	-10.28%	-10.39%
Operating CF Growth %	-0.63%	0.14%	0.11%	0.31%	-0.07%	0.13%	-2.26%	-0.25%	-0.03%	0.32%
Net Income	-32.02M	-16.21M	-26.41M	-8.64M	-20.24M	-21.82M	-58.37M	-86.8M	-63.08M	-54.05M
Depreciation & Amortization	1.61M	1.67M	1.53M	450K	60.61K	102.11K	229K	480K	704K	1.97M
Stock-Based Compensation	1.23M	1.55M	1.57M	1.63M	884.09K	660K	6.96M	10.54M	9.22M	7.43M
Deferred Taxes	321K	-14.21M	1.54M	-17.14M	3.19M	0	-52K	0	0	0
Other Non-Cash Items	-322K	-533K	-543K	10.73M	2.33M	7.56M	799K	6.51M	4.26M	-1.15M
Working Capital Changes	-851K	1.99M	-706K	-2.81M	-3.11M	-1.21M	2.49M	9.2M	-13.16M	3.67M
Change in Receivables	0	0	0	0	0	0	0	0	0	0
Change in Inventory	0	0	0	0	0	0	0	0	0	0
Change in Payables	-2.63M	-304K	-1.21M	-375K	-1.63B	-540.85M	3.5M	0	0	0
Cash from Investing+	-1.95M	-320K	-1.23M	-1.11M	-2.36M	-306.82K	-1.82M	-16.97M	3.08M	-3.38M
Capital Expenditures	-1.95M	-320K	-276K	-2.01M	-29.45K	-306.82K	-939K	-4.46M	-10.48M	-3.38M
CapEx % of Revenue	-	-	-	-	-	7.14%	-	1.79%	1.74%	0.83%
Acquisitions	-	-	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-	-	-
Other Investing	0	0	0	0	-273	0	-877K	761K	0	0
Cash from Financing+	4.37M	27.05M	-577K	25.35M	25.07M	31.61M	120.68M	59.48M	20.88M	64.86M
Debt Issued (Net)	-	-	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-	-	-
Dividends Paid	0	0	0	0	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-	-	-	-	-
Other Financing	39K	2K	6K	3K	0	-1.48M	-8.53M	-592K	-68K	-3.7M
Net Change in Cash	-	-	-	-	-	-	-	-	-	-
Free Cash Flow+	-31.98M	-26.06M	-23.3M	-17.79M	-16.92M	-15.02M	-48.88M	-64.54M	-72.53M	-45.53M
FCF Margin %	-	-	-	-	-	-349.2%	-	-25.94%	-12.02%	-11.23%
FCF Growth %	-0.47%	0.19%	0.11%	0.24%	0.05%	0.11%	-2.26%	-0.32%	-0.12%	0.37%
FCF per Share	-145.03	-108.65	-61.66	-28.78	-1.22	-0.13	-0.25	-0.30	-0.30	-0.17
FCF Conversion (FCF/Net Income)	0.94x	1.59x	0.87x	1.83x	0.83x	0.67x	0.82x	0.69x	0.98x	0.78x
Interest Paid	94K	66K	30K	1K	0	0	0	0	0	0
Taxes Paid	79K	257K	197K	105K	0	0	0	0	0	0

Key Ratios

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	-77.72%	-77.62%	-2297.87%	-	-383.38%	-134.01%	-99.46%	-102.24%	-110.14%	-154.01%
Return on Invested Capital (ROIC)	-	-	-	-	-	-640.73%	-2088.84%	-1920.19%	-907.21%	-704.18%
Gross Margin	-	-	-	-	-	-14676.74%	-	100%	88.34%	51.47%
Net Margin	-	-	-	-	-	-50748.84%	-	-3488.91%	-1045.03%	-1333.02%
Debt / Equity	0.05x	0.06x	-	-	0.13x	0.12x	0.03x	0.09x	0.17x	1.10x
Interest Coverage	-	-	-186.19x	-184.71x	-8.01x	-29.52x	-734.53x	-	-	-
FCF Conversion	0.94x	1.59x	0.87x	1.83x	0.83x	0.67x	0.82x	0.69x	0.98x	0.78x
Revenue Growth	-	-	-	-	-	-	-100%	-	142.6%	-32.82%

Frequently Asked Questions

Growth & Financials

Ocugen, Inc. (OCGN) reported $5.4M in revenue for fiscal year 2024. This represents a 20554% increase from $0.0M in 2012.

Ocugen, Inc. (OCGN) saw revenue decline by 32.8% over the past year.

Ocugen, Inc. (OCGN) reported a net loss of $64.0M for fiscal year 2024.

Dividend & Returns

Ocugen, Inc. (OCGN) has a return on equity (ROE) of -154.0%. Negative ROE indicates the company is unprofitable.

Ocugen, Inc. (OCGN) had negative free cash flow of $53.5M in fiscal year 2024, likely due to heavy capital investments.

US Stock Screener

...

Ocugen, Inc. (OCGN) 10-Year Financial Performance & Capital Metrics

OCGN • • Industrial / General

HealthcareBiotechnologyRare Genetic DiseasesGene Therapy & Rare Diseases

Revenue $4M -32.8%
EBITDA -$53M +18.6%
Net Income -$54M +14.3%
EPS (Diluted) -0.20 +23.1%
Gross Margin 51.47% -41.7%
EBITDA Margin -1301.82% -21.2%
Operating Margin -1350.36% -24.4%
Net Margin -1333.02% -27.6%
ROE -154.01% -39.8%
ROIC -704.18% +22.4%
Debt/Equity 1.10 +541.0%
Interest Coverage -

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Momentum leader: RS Rating 92 (top 8%)

✗Weaknesses

✗Weak Piotroski F-Score: 2/9
✗Negative free cash flow
✗Shares diluted 10.9% in last year
✗Expensive at 14.8x book value
✗Low asset turnover indicates capital-intensive operations

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-

5Y-

3Y-

TTM-42.43%

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM-28.9%

EPS CAGR

10Y-

5Y-

3Y-

TTM-23.32%

ROCE

10Y Avg-120.06%

5Y Avg-103.27%

3Y Avg-101.15%

Latest-101.11%

Peer Comparison

Gene Therapy & Rare Diseases

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
KRYSKrystal Biotech, Inc.	8.18B	282.01	94.00	473.02%	53.3%	17.48%	1.46%	0.01
BMRNBioMarin Pharmaceutical Inc.	10.58B	55.07	24.92	17.97%	16.82%	8.59%	4.49%	0.11
SRPTSarepta Therapeutics, Inc.	2.23B	21.31	9.11	52.97%	-11.25%	-20.57%		0.88
RAREUltragenyx Pharmaceutical Inc.	2.27B	23.50	-3.74	29.01%	-91.95%	-35.88%		0.15
DYNDyne Therapeutics, Inc.	2.7B	16.42	-4.87			-61.26%		0.04
TVTXTravere Therapeutics, Inc.	2.54B	28.40	-6.96	60.55%	-20.32%	-120.36%		6.80
BEAMBeam Therapeutics Inc.	3.25B	32.05	-7.00	-83.18%	-7.44%	-42.92%		0.22
SLNOSoleno Therapeutics, Inc.	2.25B	41.95	-9.58		-79.5%	-15.85%		0.22

Profit & Loss

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	0	0	0	0	0	43K	0	2.49M	6.04M	4.05M
Revenue Growth %	-	-	-	-	-	-	-1%	-	1.43%	-0.33%
Cost of Goods Sold+	1.61M	1.67M	1.53M	49.62K	8.09M	6.35M	0	0	704K	1.97M
COGS % of Revenue	-	-	-	-	-	147.77%	-	-	0.12%	0.49%
Gross Profit+	-1.61M	-1.67M	-1.53M	-49.62K	-8.09M	-6.31M	0	2.49M	5.33M	2.09M
Gross Margin %	-	-	-	-	-	-146.77%	-	1%	0.88%	0.51%
Gross Profit Growth %	-	-0.04%	0.08%	0.97%	-161.95%	0.22%	1%	-	1.14%	-0.61%
Operating Expenses+	31.51M	30.11M	24.95M	25.84M	6.08M	14.97M	58.03M	91.56M	70.86M	56.84M
OpEx % of Revenue	-	-	-	-	-	348.23%	-	36.8%	11.74%	14.02%
Selling, General & Admin	8.27M	8.53M	9.38M	10.2M	6.08M	7.97M	22.92M	35.4M	31.99M	26.69M
SG&A % of Revenue	-	-	-	-	-	185.44%	-	14.23%	5.3%	6.58%
Research & Development	23.24M	21.58M	15.57M	15.63M	8.09M	13.35M	35.11M	56.16M	39.57M	32.13M
R&D % of Revenue	-	-	-	-	-	310.56%	-	22.57%	6.56%	7.92%
Other Operating Expenses	-72K	-248K	-116K	0	-8.09M	-6.35M	0	0	-704K	-1.97M
Operating Income+	-31.82M	-30.31M	-24.95M	-30.11M	-14.16M	-21.29M	-58.03M	-89.07M	-65.53M	-54.76M
Operating Margin %	-	-	-	-	-	-495%	-	-35.8%	-10.86%	-13.5%
Operating Income Growth %	0.03%	0.05%	0.18%	-0.21%	0.53%	-0.5%	-1.73%	-0.53%	0.26%	0.16%
EBITDA+	-30.2M	-28.63M	-23.42M	-30.06M	-14.1M	-21.18M	-57.8M	-88.59M	-64.83M	-52.79M
EBITDA Margin %	-	-	-	-	-	-492.63%	-	-35.61%	-10.74%	-13.02%
EBITDA Growth %	0.05%	0.05%	0.18%	-0.28%	0.53%	-0.5%	-1.73%	-0.53%	0.27%	0.19%
D&A (Non-Cash Add-back)	1.61M	1.67M	1.53M	49.62K	61K	102K	229K	480K	704K	1.97M
EBIT	-31.89M	-13.05M	-26.41M	-14.47M	-14.16M	-14.29M	-58.03M	-89.07M	-65.53M	-54.76M
Net Interest Income+	0	0	0	0	-1.77M	-719.9K	-79K	1.4M	2.5M	1.3M
Interest Income	0	0	0	0	1.21K	1.06K	0	1.4M	2.5M	1.3M
Interest Expense	-133K	-60K	134K	163K	1.77M	720.96K	79K	0	0	0
Other Income/Expense	-205K	14.1M	-1.46M	11.89M	-6.08M	-537K	-389K	2.27M	2.45M	703K
Pretax Income+	-32.02M	-16.21M	-26.41M	-8.64M	-20.24M	-21.82M	-58.42M	-86.8M	-63.08M	-54.05M
Pretax Margin %	-	-	-	-	-	-507.49%	-	-34.89%	-10.45%	-13.33%
Income Tax+	0	0	-186K	-15.76M	0	0	-52K	0	0	0
Effective Tax Rate %	1%	1%	1%	1%	1%	1%	1%	1%	1%	1%
Net Income+	-32.02M	-16.21M	-26.41M	-8.64M	-20.24M	-21.82M	-58.37M	-86.8M	-63.08M	-54.05M
Net Margin %	-	-	-	-	-	-507.49%	-	-34.89%	-10.45%	-13.33%
Net Income Growth %	-0.4%	0.49%	-0.63%	0.67%	-1.34%	-0.08%	-1.67%	-0.49%	0.27%	0.14%
Net Income (Continuing)	-32.02M	-16.21M	-26.41M	-18.22M	-20.24M	-21.82M	-58.37M	-86.8M	-63.08M	-54.05M
Discontinued Operations	0	0	0	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0
EPS (Diluted)+	-145.22	-67.58	-69.91	-13.98	-1.53	-0.31	-0.30	-0.40	-0.26	-0.20
EPS Growth %	0.84%	0.53%	-0.03%	0.8%	0.89%	0.8%	0.03%	-0.33%	0.35%	0.23%
EPS (Basic)	-145.22	-68.21	-69.91	-13.98	-1.53	-0.31	-0.30	-0.40	-0.26	-0.20
Diluted Shares Outstanding	220.52K	239.82K	377.84K	618.18K	13.89M	112.24M	195.01M	214.6M	244.33M	271M
Basic Shares Outstanding	220.52K	237.62K	377.83K	618.18K	13.89M	112.24M	195.01M	214.6M	244.33M	271M
Dividend Payout Ratio	-	-	-	-	-	-	-	-	-	-

Balance Sheet

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	31.24M	32.08M	8.18M	16.4M	15.77M	25.88M	102.65M	98.49M	42.97M	61.68M
Cash & Short-Term Investments	30.91M	31.91M	7.98M	15.54M	7.44M	24.04M	94.96M	90.93M	39.46M	58.51M
Cash Only	30.91M	31.91M	7.08M	15.54M	7.44M	24.04M	94.96M	77.56M	39.46M	58.51M
Short-Term Investments	0	0	900K	0	0	0	0	13.37M	0	0
Accounts Receivable	0	0	0	0	0	0	0	0	0	0
Days Sales Outstanding	-	-	-	-	-	-	-	-	-	-
Inventory	0	0	0	0	0	0	0	0	0	0
Days Inventory Outstanding	-	-	-	-	-	-	-	-	-	-
Other Current Assets	279K	78K	122K	172K	7M	0	0	7.56M	3.51M	3.17M
Total Non-Current Assets+	5.55M	4M	2.86M	1.03M	1.04M	1.5M	3.12M	10.14M	21.58M	20.76M
Property, Plant & Equipment	5.21M	3.86M	2.72M	141K	222.46K	633K	1.16M	6.05M	17.29M	16.55M
Fixed Asset Turnover	-	-	-	-	-	0.07x	-	0.41x	0.35x	0.24x
Goodwill	0	0	0	0	0	0	0	0	0	0
Intangible Assets	200K	0	0	0	0	0	0	0	0	0
Long-Term Investments	0	0	137K	150.48K	151.02K	0	0	0	0	0
Other Non-Current Assets	137K	137K	0	736.52K	667.75K	865K	1.95M	4.09M	4.29M	4.21M
Total Assets+	36.79M	36.08M	11.04M	17.43M	16.81M	27.38M	105.76M	108.63M	64.55M	82.44M
Asset Turnover	-	-	-	-	-	0.00x	-	0.02x	0.09x	0.05x
Asset Growth %	-0.44%	-0.02%	-0.69%	0.58%	-0.04%	0.63%	2.86%	0.03%	-0.41%	0.28%
Total Current Liabilities+	6.36M	5.17M	3.81M	2.87M	4.54M	3.61M	7M	28.53M	17.09M	21.59M
Accounts Payable	2.25M	1.95M	776K	1.59M	1.9M	395K	2.31M	8.06M	3.17M	4.24M
Days Payables Outstanding	509.51	425	184.64	11.7K	85.57	22.69	-	-	1.64K	786.94
Short-Term Debt	583K	583K	178K	0	0	234K	0	0	0	1.33M
Deferred Revenue (Current)	1000K	1000K	1000K	1000K	1000K	0	0	1000K	1000K	1000K
Other Current Liabilities	2.77M	1.24M	1.18M	948K	-2.06M	1.68M	1.72M	3.11M	1.03M	5.25M
Current Ratio	4.91x	6.20x	2.15x	5.71x	3.47x	7.16x	14.66x	3.45x	2.51x	2.86x
Quick Ratio	4.91x	6.20x	2.15x	5.71x	3.47x	7.16x	14.66x	3.45x	2.51x	2.86x
Cash Conversion Cycle	-	-	-	-	-	-	-	-	-	-
Total Non-Current Liabilities+	2.23M	17.34M	18.5M	15.01M	1.25M	2.21M	2.94M	6.12M	6.89M	31.22M
Long-Term Debt	761K	178K	0	1.02M	1.07M	1.82M	1.71M	2.29M	2.8M	27.34M
Capital Lease Obligations	0	0	0	0	163.2K	389K	1.23M	3.59M	3.57M	3.31M
Deferred Tax Liabilities	0	0	0	-1.02M	0	0	0	0	918K	0
Other Non-Current Liabilities	1.47M	17.16M	18.5M	4M	9.76K	0	0	244K	527K	564K
Total Liabilities	8.59M	22.51M	22.3M	17.89M	5.79M	5.83M	9.94M	34.65M	23.98M	52.81M
Total Debt+	1.34M	761K	178K	238K	1.41M	2.49M	3.31M	6.37M	6.94M	32.5M
Net Debt	-29.57M	-31.15M	-6.9M	-15.3M	-6.04M	-21.55M	-91.65M	-71.19M	-32.52M	-26.01M
Debt / Equity	0.05x	0.06x	-	-	0.13x	0.12x	0.03x	0.09x	0.17x	1.10x
Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Net Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Interest Coverage	-	-	-186.19x	-184.71x	-8.01x	-29.52x	-734.53x	-	-	-
Total Equity+	28.2M	13.57M	-11.27M	-458K	11.02M	21.55M	95.82M	73.98M	40.56M	29.63M
Equity Growth %	-0.48%	-0.52%	-1.83%	0.96%	25.06%	0.96%	3.45%	-0.23%	-0.45%	-0.27%
Book Value per Share	127.87	56.57	-29.82	-0.74	0.79	0.19	0.49	0.34	0.17	0.11
Total Shareholders' Equity	28.2M	13.57M	-11.27M	-458K	11.02M	21.55M	95.82M	73.98M	40.56M	29.63M
Common Stock	132K	159K	159K	513K	527.47K	1.84M	2M	2.22M	2.57M	2.92M
Retained Earnings	-165.56M	-181.77M	-208.19M	-216.83M	-51.48M	-73.3M	-131.67M	-223.09M	-286.17M	-340.22M
Treasury Stock	0	0	0	0	-47.86K	-48K	-48K	-48K	-48K	-48K
Accumulated OCI	-7.99M	-9.39M	-10.92M	-10.29M	0	0	0	26K	20K	48K
Minority Interest	0	0	0	0	0	0	0	0	0	0

Cash Flow

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	-30.03M	-25.74M	-23.02M	-15.78M	-16.89M	-14.71M	-47.94M	-60.08M	-62.05M	-42.14M
Operating CF Margin %	-	-	-	-	-	-342.06%	-	-24.15%	-10.28%	-10.39%
Operating CF Growth %	-0.63%	0.14%	0.11%	0.31%	-0.07%	0.13%	-2.26%	-0.25%	-0.03%	0.32%
Net Income	-32.02M	-16.21M	-26.41M	-8.64M	-20.24M	-21.82M	-58.37M	-86.8M	-63.08M	-54.05M
Depreciation & Amortization	1.61M	1.67M	1.53M	450K	60.61K	102.11K	229K	480K	704K	1.97M
Stock-Based Compensation	1.23M	1.55M	1.57M	1.63M	884.09K	660K	6.96M	10.54M	9.22M	7.43M
Deferred Taxes	321K	-14.21M	1.54M	-17.14M	3.19M	0	-52K	0	0	0
Other Non-Cash Items	-322K	-533K	-543K	10.73M	2.33M	7.56M	799K	6.51M	4.26M	-1.15M
Working Capital Changes	-851K	1.99M	-706K	-2.81M	-3.11M	-1.21M	2.49M	9.2M	-13.16M	3.67M
Change in Receivables	0	0	0	0	0	0	0	0	0	0
Change in Inventory	0	0	0	0	0	0	0	0	0	0
Change in Payables	-2.63M	-304K	-1.21M	-375K	-1.63B	-540.85M	3.5M	0	0	0
Cash from Investing+	-1.95M	-320K	-1.23M	-1.11M	-2.36M	-306.82K	-1.82M	-16.97M	3.08M	-3.38M
Capital Expenditures	-1.95M	-320K	-276K	-2.01M	-29.45K	-306.82K	-939K	-4.46M	-10.48M	-3.38M
CapEx % of Revenue	-	-	-	-	-	7.14%	-	1.79%	1.74%	0.83%
Acquisitions	-	-	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-	-	-
Other Investing	0	0	0	0	-273	0	-877K	761K	0	0
Cash from Financing+	4.37M	27.05M	-577K	25.35M	25.07M	31.61M	120.68M	59.48M	20.88M	64.86M
Debt Issued (Net)	-	-	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-	-	-
Dividends Paid	0	0	0	0	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-	-	-	-	-
Other Financing	39K	2K	6K	3K	0	-1.48M	-8.53M	-592K	-68K	-3.7M
Net Change in Cash	-	-	-	-	-	-	-	-	-	-
Free Cash Flow+	-31.98M	-26.06M	-23.3M	-17.79M	-16.92M	-15.02M	-48.88M	-64.54M	-72.53M	-45.53M
FCF Margin %	-	-	-	-	-	-349.2%	-	-25.94%	-12.02%	-11.23%
FCF Growth %	-0.47%	0.19%	0.11%	0.24%	0.05%	0.11%	-2.26%	-0.32%	-0.12%	0.37%
FCF per Share	-145.03	-108.65	-61.66	-28.78	-1.22	-0.13	-0.25	-0.30	-0.30	-0.17
FCF Conversion (FCF/Net Income)	0.94x	1.59x	0.87x	1.83x	0.83x	0.67x	0.82x	0.69x	0.98x	0.78x
Interest Paid	94K	66K	30K	1K	0	0	0	0	0	0
Taxes Paid	79K	257K	197K	105K	0	0	0	0	0	0

Key Ratios

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	-77.72%	-77.62%	-2297.87%	-	-383.38%	-134.01%	-99.46%	-102.24%	-110.14%	-154.01%
Return on Invested Capital (ROIC)	-	-	-	-	-	-640.73%	-2088.84%	-1920.19%	-907.21%	-704.18%
Gross Margin	-	-	-	-	-	-14676.74%	-	100%	88.34%	51.47%
Net Margin	-	-	-	-	-	-50748.84%	-	-3488.91%	-1045.03%	-1333.02%
Debt / Equity	0.05x	0.06x	-	-	0.13x	0.12x	0.03x	0.09x	0.17x	1.10x
Interest Coverage	-	-	-186.19x	-184.71x	-8.01x	-29.52x	-734.53x	-	-	-
FCF Conversion	0.94x	1.59x	0.87x	1.83x	0.83x	0.67x	0.82x	0.69x	0.98x	0.78x
Revenue Growth	-	-	-	-	-	-	-100%	-	142.6%	-32.82%

Frequently Asked Questions

Growth & Financials

Ocugen, Inc. (OCGN) reported $5.4M in revenue for fiscal year 2024. This represents a 20554% increase from $0.0M in 2012.

Ocugen, Inc. (OCGN) saw revenue decline by 32.8% over the past year.

Ocugen, Inc. (OCGN) reported a net loss of $64.0M for fiscal year 2024.

Dividend & Returns

Ocugen, Inc. (OCGN) has a return on equity (ROE) of -154.0%. Negative ROE indicates the company is unprofitable.

Ocugen, Inc. (OCGN) had negative free cash flow of $53.5M in fiscal year 2024, likely due to heavy capital investments.